Adeza is the maker of FullTerm™, The Fetal Fibronectin Test, which is used to help assess the risk of premature birth from 22 to 35 weeks of pregnancy, and E-tegrity®, a test that measures endometrial receptivity to increase the chance of a successful pregnancy in women who are having difficulty getting pregnant.  Adeza’s mission is to ensure the healthiest possible, cost-effective outcome for women and their families. Adeza is committed to become a leader in women's healthcare – providing leading edge technology in medical diagnostics, laboratory services, research and product development.